Transient responses to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic leukemia/lymphoma

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Rakowski, Lesley A ^a,b   Lehotzky, Erica A ^a,b   Chiang, Mark Y ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A; CHEMOKINE RECEPTOR CCR7; COMPLEMENTARY DNA; DOXYCYCLINE; GLUCOSE TRANSPORTER 3; HIGH MOBILITY GROUP A2 PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; NOTCH RECEPTOR; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HOX11; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR TLX1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HOMEODOMAIN PROTEIN; ONCOPROTEIN; TLX1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CD4 CD8 RATIO; CELL CYCLE PROGRESSION; CELL LINEAGE; CONTROLLED STUDY; DNA SEQUENCE; EXON; IN VIVO STUDY; MOUSE; NONHUMAN; PENETRANCE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; WESTERN BLOTTING; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CULTURE; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; T CELL LEUKEMIA; TIME; TRANSGENIC MOUSE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS; RECEPTOR, NOTCH1; TIME FACTORS;

EID: 79951543448     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016761     Document Type: Article

References (51)

1. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, et al. (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1: 75-87.
2. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271.
3. Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison CJ, et al. (2009) Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 23: 125-133.
4. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, et al. (2007) Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 39: 593-595.
5. Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 42: 338-342.
6. Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet 42: 530-535.
7. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, et al. (2009) WT1 mutations in T-ALL. Blood 114: 1038-1045.
8. Roberts CW, Shutter JR, Korsmeyer SJ, (1994) Hox11 controls the genesis of the spleen. Nature 368: 747-749.
9. Dear TN, Sanchez-Garcia I, Rabbitts TH, (1993) The HOX11 gene encodes a DNA-binding nuclear transcription factor belonging to a distinct family of homeobox genes. Proceedings of the National Academy of Sciences of the United States of America 90: 4431-4435.
10. Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ, (1991) Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science 253: 79-82.
11. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, et al. (2004) Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet 363: 535-536.
12. Bergeron J, Clappier E, Radford I, Buzyn A, Millien C, et al. (2007) Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood 110: 2324-2330.
13. Kopan R, Ilagan MX, (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216-233.
14. Chiang MY, Xu ML, Histen G, Shestova O, Roy M, et al. (2006) Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1. Mol Cell Biol 26: 6261-6271.
15. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, et al. (2007) FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to {gamma}-secretase inhibitors. J Exp Med 204: 1813-1824.
16. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, et al. (2007) The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 204: 1825-1835.
17. Fryer CJ, White JB, Jones KA, (2004) Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 16: 509-520.
18. Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, et al. (2009) NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 113: 3918-3924.
19. Malecki MJ, Sanchez-Irizarry C, Mitchell JL, Histen G, Xu ML, et al. (2006) Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol Cell Biol 26: 4642-4651.
20. Dudley DD, Wang HC, Sun XH, (2009) Hes1 potentiates T cell lymphomagenesis by up-regulating a subset of notch target genes. PLoS One 4: e6678.
21. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, et al. (2007) Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210.
22. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, et al. (2006) NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 103: 18261-18266.
23. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, et al. (2006) c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20: 2096-2109.
24. Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, et al. (2006) Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol 26: 8022-8031.
25. Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, et al. (2009) Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 113: 6172-6181.
26. Dube ID, Kamel RS, Yuan CC, Lu M, Wu X, et al. (1991) A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood 78: 2996-3003.
27. Kennedy MA, Gonzalez-Sarmiento R, Kees UR, Lampert F, Dear N, et al. (1991) HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24. Proceedings of the National Academy of Sciences of the United States of America 88: 8900-8904.
28. Hawley RG, Fong AZ, Reis MD, Zhang N, Lu M, et al. (1997) Transforming function of the HOX11/TCL3 homeobox gene. Cancer Res 57: 337-345.
29. Hough MR, Reis MD, Singaraja R, Bryce DM, Kamel-Reid S, et al. (1998) A model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice. Proc Natl Acad Sci U S A 95: 13853-13858.
30. Su X, Drabkin H, Clappier E, Morgado E, Busson M, et al. (2006) Transforming potential of the T-cell acute lymphoblastic leukemia-associated homeobox genes HOXA13, TLX1, and TLX3. Genes Chromosomes Cancer 45: 846-855.
31. Labrecque N, Whitfield LS, Obst R, Waltzinger C, Benoist C, et al. (2001) How much TCR does a T cell need? Immunity 15: 71-82.
32. Gonzalez-Garcia S, Garcia-Peydro M, Martin-Gayo E, Ballestar E, Esteller M, et al. (2009) CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia. Journal of Experimental Medicine 206: 779-791.
33. Riz I, Hawley TS, Johnston H, Hawley RG, (2009) Role of TLX1 in T-cell acute lymphoblastic leukaemia pathogenesis. Br J Haematol 145: 140-143.
34. Greene WK, Bahn S, Masson N, Rabbitts TH, (1998) The T-cell oncogenic protein HOX11 activates Aldh1 expression in NIH 3T3 cells but represses its expression in mouse spleen development. Molecular & Cellular Biology 18: 7030-7037.
35. Della Gatta G, Palomero T, Luisa Sulis M, Solé X, Lim WK, et al. (2009) Oncogenic Transcriptional Programs Controlled by TLX1/HOX11 and TLX3/HOX11L2 in T-ALL. Blood (ASH Annual Meeting Abstracts) 114.
36. De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med 16: 1321-1327.
37. Riz I, Hawley TS, Luu TV, Lee NH, Hawley RG, TLX1 and NOTCH coregulate transcription in T cell acute lymphoblastic leukemia cells. Mol Cancer 9: 181.
38. Aster JC, Pear WS, Blacklow SC, (2007) Notch Signaling in Leukemia. Annu Rev Pathol 3: 587-613.
39. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, et al. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698.
40. Spaulding C, Reschly EJ, Zagort DE, Yashiro-Ohtani Y, Beverly LJ, et al. (2007) Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood 110: 2650-2658.
41. Wilson A, Radtke F, (2006) Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Lett 580: 2860-2868.
42. Chiang MY, Childs ME, Romany C, Shestova O, Aster J, et al. (2009) C-Myc but not AKT can substitute for Notch in lymphomagenesis. Blood (ASH Annual Meeting Abstracts) 114.
43. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ, (2007) Notch signals positively regulate activity of the mTOR pathway in T cell acute lymphoblastic leukemia. Blood 110: 278-286.
44. De Keersmaecker K, Real Luna PJ, G DG, Palomero T, Castillo M, et al. (2009) The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL. Blood (ASH Annual Meeting Abstracts) 114.
45. Owens BM, Hawley TS, Spain LM, Kerkel KA, Hawley RG, (2006) TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J Haematol 132: 216-229.
46. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, et al. (1999) CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99: 23-33.
47. Kwan J, Killeen N, (2004) CCR7 directs the migration of thymocytes into the thymic medulla. Journal of Immunology 172: 3999-4007.
48. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, et al. (2005) Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963.
49. Chiang MY, Xu L, Shestova O, Histen G, L'Heureux S, et al. (2008) Leukemia-associated NOTCH mutations are weak tumor initiators, but accelerate K-ras-initiated leukemia. Journal of Clinical Investigation 118: 14.
50. Maillard I, Koch U, Dumortier A, Shestova O, Xu L, et al. (2008) Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell 2: 356-366.
51. Lin YW, Nichols RA, Letterio JJ, Aplan PD, (2006) Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 107: 2540-2543.